![Arthur Lieberman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Arthur Lieberman
Keine laufenden Positionen mehr
Karriereverlauf von Arthur Lieberman
Ehemalige bekannte Positionen von Arthur Lieberman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TYRX, Inc.
![]() TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Direktor/Vorstandsmitglied | 26.07.2010 | - |
Ausbildung von Arthur Lieberman
Cornell University | Undergraduate Degree |
Brooklyn Law School | Graduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Director/Board Member | 1 |
Sektoral
Consumer Services | 3 |
Electronic Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
TYRX, Inc.
![]() TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Technology |
- Börse
- Insiders
- Arthur Lieberman
- Erfahrung